NHS Federated Data Platform

Iqbal Mohamed Excerpts

Thursday 16th April 2026 Westminster Hall

[Iqbal Mohamed (Dewsbury and Batley) (Ind)]

It is a pleasure to serve under your chairship, Dame Siobhain.

In a briefing for investors, Palantir chief executive officer Alex Karp said:

“we are super proud of the role we play, especially in places we can’t talk about…Palantir is here to disrupt…and when it’s necessary, to scare our enemies and on occasion kill them.”

If it looks evil, if it smells evil and if it behaves evil, then it is evil. I thank the hon. Member for Newton Abbot (Martin Wrigley) for securing this debate. Given my lack of speaking time, I am going to have to cut my speech short.

We must examine Palantir’s record elsewhere in the world in our assessment of its suitability as a supplier to the NHS. Palantir has long-standing contracts with United States Immigration and Customs Enforcement, and the tools to track and target migrants that it has provided to ICE have facilitated racial profiling, family separation and violations of due process. In January 2024, Palantir entered into a strategic partnership with the Israeli Ministry of Defence to support war-related missions, meaning that its advanced data systems are used to perpetuate a genocide against the Palestinian people. Reports from Novara Media and the Financial Times state that NHS staff have been warned that they could be fired for criticising the NHS contract with Palantir, that NHS organisations are under pressure to sign up voluntarily to the Palantir data system, and that technicians have been told to stop working on alternate systems.

The Swiss Government have previously rejected engagement with Palantir, raising national security concerns; in the US, hospital systems in New York have moved away from Palantir arrangements, citing data governance and control issues; and here at home, uptake of the FDP remains uneven, with many NHS professionals reluctant—in some cases refusing—to engage with it. Perhaps most concerning of all are the reports that patient data opt-outs do not apply to the federated data platform due to a legal direction issued under section 254 of the Health and Social Care Act 2012, yet that direction has not been published or named or been subject to scrutiny. This debate is not about technology; it is about who we trust to sit at the heart of our NHS, and on that question, the Government must think again.

--- Later in debate ---

[Navendu Mishra (Stockport) (Lab)]

It is a pleasure to serve under your chairship, Dame Siobhain. I thank the hon. Member for Newton Abbot (Martin Wrigley) for securing the debate.

From links to serious human rights abuses to an ongoing lack of clarity around the security of sensitive patient data, a large number of my constituents have raised concerns about the ethical implications of using Palantir technology in our NHS. The hon. Member mentioned that a newspaper report in The Times on 9 April told us that the data chief of the NHS remains committed to the use of Palantir’s technology across the health service despite the company’s ties with ICE and the US military. I have written to the chief executive of Stockport NHS foundation trust as well as the Greater Manchester ICB on that issue.

Amnesty International and Medact, an organisation that brings together health workers in the UK, have been vocal in urging hospitals not to use Palantir software and have highlighted the link to some very concerning instances of human rights abuses.

[Iqbal Mohamed]

Will the hon. Member give way?

[Navendu Mishra]

I am limited for time and the hon. Member has already contributed, so I ask him to accept my apologies.

Patients must feel confident that their data is handled transparently, securely and in a way that reflects British values. That is why we should be investing in and developing our own sovereign technological capabilities here in Britain. I want to see Britain at the forefront of science and technology, and that starts with backing our own institutions. The UK has a proud heritage of education, with some of the finest universities and institutions in the world. We should be investing in them instead of relying heavily on foreign companies.

France has set a good example here. The French Government are moving all their desktops from Windows to Linux as part of a nationwide strategy to reduce reliance on US tech giants. We should take similar action in the UK. Retendering the federated data platform could benefit the country, addressing ethical and security concerns while also delivering long-term economic and technological benefits. I know the Minister is an NHS worker—a transplant surgeon—and on behalf of the people of Stockport, I thank him for the work that he does for the NHS. I know he will take seriously the point that it is not just the cost of the £330 million to the British taxpayer that cross-party Members here are concerned about; they are also concerned about their private, personal health data and the ethical behaviour of Palantir. I hope he will take the concerns raised today urgently back to the Government.

--- Later in debate ---

[Dr Danny Chambers (Winchester) (LD)]

It is an honour to serve under your chairpersonship, Dame Siobhain. I thank my hon. Friend the Member for Newton Abbot (Martin Wrigley) for his tenacity and expertise in this subject. He has done a huge amount of research, and made an absolutely excellent speech.

At a moment of rising global instability, it is extraordinary that we are prepared to trust the health of our citizens and the functioning of our NHS to a US corporation that does not share our values or interests. Outsourcing the storage, handling and analysis of NHS data to a foreign company, rather than securing the national and economic benefits of this work being done by a British or UK-led organisation, is yet another example of our unnecessary reliance on others to keep our vital infrastructure running. Doctors and the public have made it clear that they do not trust this company. Fewer than half of NHS trusts have begun using this technology, in large part because of the concern from patients and clinicians. If, as the Health Secretary says, the federated data platform is

“absolutely critical to the future of the NHS”,

placing it in the hands of a company that staff and patients do not trust risks undermining that future from the outset.

This is the central issue: we hold doctors and nurses to the highest ethical standards, and rightly so. We expect them to protect confidentiality, to act with integrity and to put patients first. So why are we asking them to use a system they do not trust and stake their professional reputations on it?

Palantir is not a neutral contractor. It is a company that is deeply embedded within the political ecosystem of Donald Trump, a convicted felon whose Administration has repeatedly undermined the international rule of law. It is a company that has worked hand in glove with US Immigration and Customs Enforcement, whose behaviour is morally and legally outrageous and whose agents have operated like masked vigilantes in the deportation of individuals. We are all aware of the tragedies that that rogue Trump organisation has left in its wake. Why are we allowing a Trump-aligned company to sit at the heart of Britain’s most precious public service? Why are we comfortable placing NHS data in the hands of a company whose values are so clearly at odds with those of the British public?

This is not a technical decision—this is a political choice. The NHS is not only one of our most important public services but one of the largest areas of public spending. Therefore, it is deeply concerning that Palantir’s contract for the federated data platform is so heavily redacted that it makes scrutiny almost impossible.

[Iqbal Mohamed]

Health inequality in the NHS for people of ethnic minorities is a challenge that we need to address. The New Orleans police department and the Los Angeles police department both terminated Palantir-powered predictive policing due to the system’s reinforcing racial bias and creating feedback loops to overpoliced communities that were affected. Does the hon. Member agree not only that the company and its leaders are unethical but that the systems it supplies are unethical and racist?

[Dr Chambers]

That is an important point. Amnesty International, whose representatives I believe are present, and others including voices within the NHS have been raising serious concerns about the potential misuse or inappropriate sharing of sensitive data. The Government must come clean about how the contract was awarded in the first place and what steps they will be taking to bring it to an end.

We should be building NHS data processing capacity here in the United Kingdom, strengthening our resilience, backing our own expertise and building sovereignty in a more dangerous world. Instead, we are exporting control of one of our most valuable national assets. I ask the Government today to use the break clause, stand with NHS staff, protect patient trust and keep Donald Trump and his allies out of our NHS.

--- Later in debate ---

[The Parliamentary Under-Secretary of State for Health and Social Care (Dr Zubir Ahmed)]

It is always a pleasure to serve under your chairmanship, Dame Siobhain. I am grateful to the hon. Member for Newton Abbot (Martin Wrigley) for securing this important debate and for his and other hon. Members’ contributions to it. Of course, we should also welcome the hon. Member for Solihull West and Shirley (Dr Shastri-Hurst) to his place in his first debate on the Front Bench.

We have heard a lot about concerns and insights and interpretations about the NHS’s technological architecture. Some would have us think that the FDP is synonymous with just one company. It is not. The FDP is fundamentally an NHS construct. It consists of multiple contracts awarded to a number of consortia, including Palantir, Accenture, PwC, Carnall Farrar and the North of England Care System Support. Each of those have different responsibilities to make sure that there is training, health expertise and security in the FDP.

Ultimately, the FDP is a federation of local trusts and ICBs within NHS England, each with their own version of the FDP and their own abilities to decide which information they put there on the basis of their own service needs and governance arrangements. Although there should be scrutiny of Palantir and of any contract, we should also provide clarity about what the FDP is delivering for the NHS. It is my duty to make sure that the FDP is improving patient and clinical experience and improving patient outcomes.

Making the best use of data generated by the NHS and social care is essential to transforming services, improving outcomes for patients and making sure that we use resources in the best manner possible. Lord Darzi’s independent investigation into the NHS found that, despite huge volumes of data, fundamentally:

“The last decade was a missed opportunity to prepare the NHS”

to use the latest technologies.

The FDP is part of an infrastructure—it is not the infrastructure or the only infrastructure—resolve that gap. It is improving efficiency and generating savings across the health service worth up to £2.4 billion, according to independent estimates. Those independent estimates are being further bolstered by a commissioned study by Imperial College that will look at the economic impact of the FDP. It is an important tool for us being able to make the NHS fit for the future on clinical efficiency, transparency of data and outcomes for patients up and down the country.

Before I go into more detail about what the FDP does, it is important that I say what it does not do. For instance, it is not synonymous with the single patient record, the NHS app or—necessarily—with linking primary care data with secondary care data.

[Iqbal Mohamed]

Will the Minister give way?

[Dr Ahmed]

I am going to carry on for a bit longer.

The hon. Member for Aberdeenshire North and Moray East (Seamus Logan) tempts me with his speech, and he knows that I cannot resist his temptation. He spoke about Scotland and he will know that I am an NHS surgeon in Scotland. I hope he thinks that I can speak with some authority about the NHS in Scotland, so let me tell him a few things about the digital architecture in the NHS there.

The NHS app has been running successfully in England for over eight years. Three out of four people in the NHS in England have that app. To clarify, the app is not Palantir; it has been devised organically on the ground by NHS England—by clinicians and by technologists. It now serves millions of patients to book test results, screenings and appointments—including GP appointments —to end the 8 am rush.

The hon. Member for Aberdeenshire North and Moray East spoke about the MyCare app in Scotland. That remains a far-fetched dream rather than a reality. The limit of the ambition of that app seems to be, as I understand it, a dermatology service in one part of Scotland called Lanarkshire, for those who are not familiar with Scotland. It is a million miles away from what has been developed down here in England.

[Dr Ahmed]

I will not; I am going to carry on—and I will tell the hon. Gentleman something further. The NHS in England was quite happy to use the expertise of technologists up and down the country, including in Scotland—including, in my own constituency of Glasgow South West, a company called Cohesion Medical. His Government in Scotland, who have been in government for over 20 years, refused that offer. That is why my patients and constituents in Scotland are unable to access simple digital services. It is why my patients and my constituents under NHS Scotland are 30 times more likely to wait over two years for treatment. It is why my patients and my constituents in Scotland are unable to access optimal stroke therapy and lung cancer screening.

The NHS federated data platform in England connects health information held in different systems, helping to manage activity to improve productivity and outcomes. By connecting critical data streams, it can accelerate diagnosis pathways, streamline discharge processes and ensure faster, more co-ordinated care that reduces waiting times for all patients.

I will briefly describe a couple of examples. North Tees and Hartlepool NHS foundation trust uses an FDP product called OPTICA to map the patient’s journey from being admitted to going home. It used to be done with spreadsheets, which were not always updated. Because of that, discharges were delayed, medicines were not sorted on time—in some cases time-critical medicines, causing real patient harm—and patients were therefore impacted. OPTICA lets the trust see all that information in one place in real time. It has reduced the number of long stays by a third, and despite a 7% increase in admissions over that time, we are improving services overall.

[Iqbal Mohamed]

Will the Minister give way?

[Dame Siobhain McDonagh (in the Chair)]

Order. May I just say that the hon. Member had very generous time allocated to him during this debate? If the Minister does not want to take an intervention, he does not need to.